Luqa signs commercialization deal with BMG Pharma in China, Hong Kong

The products included in the agreement are IaluXid, a non-antibiotic, combination gel formulation treating skin infections; oral Mucositis and Xerostomia therapies GelX and GelX Xero; and Aftacure, treating aphthous ulcers and mouth lesions.

BMG Pharma president and CEO Marco Mastrodonato said, "This long-term partnership is a major milestone for BMG as it opens us the door to the most exciting healthcare market in the world."

Luqa plans to launch the product line directly from late 2015 onwards.

Commenting on the deal, Luqa CEO Robert Braithwaite said the partnership with BMG is in line with its strategy to build a portfolio of new and high-growth potential products through targeted partnerships.

"BMG Pharma’s products complement our portfolio of innovative therapies, and we look forward to develop them into leading healthcare brands," added Braithwaite.